Business Context and Reporting Period
This Form 8-K Current Report is filed by Apimeds Pharmaceuticals US, Inc. (APUS) on July 13, 2026. The report addresses a delay in the implementation of a previously approved 1-for-10 reverse stock split and the amendment of the Company's Certificate of Incorporation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure changes rather than financial performance.
Material Changes
- Reverse Stock Split Delay: The Company originally expected the 1-for-10 reverse stock split to become effective on March 26, 2026. The filing of the Charter Amendment was delayed, and the new effective date is now set for July 24, 2026.
- Share Consolidation: Upon effectiveness, every ten (10) shares of issued and outstanding common stock will be combined into one (1) share.
- Trading Adjustments: Common stock will begin trading on a split-adjusted basis on the NYSE American LLC under the symbol "APUS" at the open of trading on July 24, 2026. The new CUSIP number will be 03771D201.
Guidance, Outlook, and Risks
Management Commentary: The Company confirmed that the required 20-day waiting period following the mailing of the Information Statement has passed. Management expects to file the Charter Amendment with the Delaware Secretary of State on or about July 23, 2026.
Contingencies: The effectiveness of the reverse stock split is contingent upon the filing of the Charter Amendment. The Company will issue a subsequent Form 8-K to announce the official effectiveness once the Effective Date occurs.
Risks: The filing does not explicitly detail new risks, though the delay in implementation may impact shareholder expectations regarding the timeline for the capital structure adjustment.
Investor Verification Checklist
- Verify the new CUSIP number (03771D201) for post-split trading.
- Confirm the exact timing of the split-adjusted trading start on July 24, 2026.
- Review the Information Statement dated February 26, 2026, for complete details on the reverse stock split rationale and terms.
- Monitor for the subsequent Form 8-K confirming the official effectiveness of the split.